These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 11822869)

  • 1. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
    Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
    Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the Ras-MEK-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt-mTOR pathways in Jaagsiekte sheep retrovirus-induced transformation of rodent fibroblast and epithelial cell lines.
    Maeda N; Fu W; Ortin A; de las Heras M; Fan H
    J Virol; 2005 Apr; 79(7):4440-50. PubMed ID: 15767444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells.
    James GL; Brown MS; Cobb MH; Goldstein JL
    J Biol Chem; 1994 Nov; 269(44):27705-14. PubMed ID: 7961691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways.
    Fukazawa H; Uehara Y
    Cancer Res; 2000 Apr; 60(8):2104-7. PubMed ID: 10786668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
    Romerio F; Riva A; Zella D
    Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms.
    Qiao L; Yacoub A; McKinstry R; Park JS; Caron R; Fisher PB; Hagan MP; Grant S; Dent P
    Cancer Biol Ther; 2002; 1(2):168-76. PubMed ID: 12170777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Ras in metal-induced EGF receptor signaling and NF-kappaB activation in human airway epithelial cells.
    Wu W; Jaspers I; Zhang W; Graves LM; Samet JM
    Am J Physiol Lung Cell Mol Physiol; 2002 May; 282(5):L1040-8. PubMed ID: 11943669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
    Miranda MB; McGuire TF; Johnson DE
    Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
    Smalley KS; Eisen TG
    Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
    Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
    J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
    Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
    Morgan MA; Dolp O; Reuter CW
    Blood; 2001 Mar; 97(6):1823-34. PubMed ID: 11238126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
    Tyagi A; Agarwal R; Agarwal C
    Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes.
    Engelman JA; Berg AH; Lewis RY; Lisanti MP; Scherer PE
    Mol Endocrinol; 2000 Oct; 14(10):1557-69. PubMed ID: 11043572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.
    Tong Z; Singh G; Rainbow AJ
    Cancer Res; 2002 Oct; 62(19):5528-35. PubMed ID: 12359764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.